Daniels Jaclyn, Kadlubar Susan
University of Arkansas for Medical Sciences, COM Department of Medical Genetics, 4301 W. Markham, #580 Little Rock, AR 72205, USA.
Pharmacogenomics. 2014 Nov;15(14):1823-1838. doi: 10.2217/pgs.14.134.
Cytosolic SULT1A1 participates in the bioconversion of a plethora of endogenous and xenobiotic substances. Genetic variation in this important enzyme such as SNPs can vary by ethnicity and have functional consequences on its activity. Most SULT1A1 genetic variability studies have been centered on the SULT1A1*1/2 SNP. Highlighted here are not only this SNP, but other genetic variants associated with SULT1A1 that could modify drug efficacy and xenobiotic metabolism. Some studies have investigated how differential metabolism of xenobiotic substances influences susceptibility to or protection from cancer in multiple sites. This review will focus primarily on the impact of SULT1A1 genetic variation on the response to anticancer therapeutic agents and subsequently how it relates to environmental and dietary exposure to both cancer-causing and cancer-preventative compounds.
胞质磺基转移酶1A1（SULT1A1）参与多种内源性和外源性物质的生物转化。该重要酶的遗传变异，如单核苷酸多态性（SNPs），可因种族而异，并对其活性产生功能影响。大多数SULT1A1遗传变异性研究都集中在SULT1A1*1/2单核苷酸多态性上。本文不仅强调了该单核苷酸多态性，还强调了与SULT1A1相关的其他遗传变异，这些变异可能会改变药物疗效和外源性物质代谢。一些研究调查了外源性物质的差异代谢如何影响多个部位癌症的易感性或对癌症的预防作用。本综述将主要关注SULT1A1基因变异对抗癌治疗药物反应的影响，以及随后它与环境和饮食中致癌和防癌化合物暴露的关系。
